Abstract
Background
Current guidelines emphasize vaccination for influenza and pneumococcus for IBD patients and the avoidance of live virus vaccines for those who are on immunosuppressive (ISS) therapy. Given the recent resurgence of measles and pertussis infections, we assessed the immune status of our IBD population in order to advise about these risks.
Methods
We prospectively collected measles and pertussis titers in our IBD patients from February 1–May 1, 2015. Immune status based on standard threshold values was determined: measles antibodies ≤0.8 antibody index (AI) = negative immunity, 0.9–1.1 AI = equivocal immunity and titers ≥1.2 AI = positive immunity. For pertussis immunity, anti-pertussis antibodies ≤5 IU/mL were considered negative immunity. Univariate analysis was performed to examine predictive factors including age, disease duration, and current medical therapies.
Results
A total of 122 patients’ titers were assessed (77 Crohn’s disease, 1 indeterminate colitis, and 45 ulcerative colitis). Sixteen (13.1 %) patients lacked detectable immunity to measles, and four (3 %) had equivocal immunity. Twelve (75 %) of the measles non-immune patients were on ISS therapy versus 65 (64 %) of 102 immune patients (OR 1.7, 95 % CI 0.5–5.9, p = 0.34). Out of 96 patients, 58 (60 %) were not immune to pertussis. Disease duration ≥10 years and age ≥50 were associated with significant lower measles titers.
Conclusions
A significant number of our IBD patients lack immunity to measles, and a majority of our IBD patients do not have detectable immunity to pertussis. Importantly, the majority of the measles non-immune patients are on ISS therapy and therefore unable to receive a booster.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240–248.
Tinsley A, Williams E, Liu G, Elwir S, Yoo L, Melmed G, Sands B. The incidence of influenza and influenza-related complications in inflammatory bowel disease patients across the united states. Presented at the 2013 Annual Scientific Meeting of the American College of Gastroenterology. San Diego, CA. 2013; Abstract 70.
Measles history. [Web]. 2014; http://www.cdc.gov/measles/about/history.html. Accessed January 1, 2016.
Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles Outbreak–California, December 2014–February 2015. [Web]. 2015; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6406a5.htm?s_cid=mm6406a5_w. Accessed April 4, 2015.
Slade TA, Klekamp BG, Rico E, Mejia-Echeverry A. Measles Outbreak in an Unvaccinated Family and a Possibly Associated International Traveler—Orange County, Florida, December 2012–January 2013. [Web]. 2014; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6336a1.htm. Accessed April 4, 2015.
Pertussis (Whooping Cough) Surveillance and Reporting. [Web]. 2015; http://www.cdc.gov/pertussis/surv-reporting.html. Accessed January 5, 2015.
Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26:293–299.
Skoff TH, Kenyon C, Cocoros N, et al. Sources of infant pertussis infection in the united states. Pediatrics. 2015;136:635–641.
Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677–692.
Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196–212.
Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the treat registry. Am J Gastroenterol. 2012;107:1409–1422.
Dezfoli S, Melmed GY. Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterol Hepatol (N Y). 2012;8:504–512.
Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148–154.
Dezfoli S, Horton HA, Thepyasuwan N, et al. Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease. Inflamm Bowel Dis.. 2015;21:1754–1760.
deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22:638–647.
Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–895.
Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–49.
Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles–mumps–rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309:2449–2456.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no relevant conflict of interest.
Rights and permissions
About this article
Cite this article
Cleveland, N.K., Rodriquez, D., Wichman, A. et al. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci 61, 2972–2976 (2016). https://doi.org/10.1007/s10620-016-4275-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-016-4275-2